Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial

Thomas M. Suter, Marion Procter, Dirk J. Van Veldhuisen, Michael Muscholl, Jonas Bergh, Chiara Carlomagno, Timothy Perren, Rodolfo Passalacqua, Claudia Bighin, Jan G.M. Klijn, Fail T. Ageev, Erika Hitre, Juergen Groetz, Hiroji Iwata, Malgorzata Knap, Michael Gnant, Susanne Muehlbauer, Alison Spence, Richard D. Gelber, Martine J. Piccart-Gebhart

Research output: Contribution to journalArticle

410 Citations (Scopus)

Abstract

Purpose: The purpose of this analysis was to investigate trastuzumab-associated cardiac adverse effects in breast cancer patients after completion of (neo)adjuvant chemotherapy with or without radiotherapy. Patients and Methods: The Herceptin Adjuvant (HERA) trial is a three-group, multicenter, open-label randomized trial that compared 1 or 2 years of trastuzumab given once every 3 weeks with observation in patients with HER-2-positive breast cancer. Only patients who after completion of (neo)adjuvant chemotherapy with or without radiotherapy had normal left ventricular ejection fraction (LVEF ≥ 55%) were eligible. A repeat LVEF assessment was performed in case of cardiac dysfunction. Results: Data were available for 1,693 patients randomly assigned to 1 year trastuzumab and 1,693 patients randomly assigned to observation. The incidence of trastuzumab discontinuation due to cardiac disorders was low (4.3%). The incidence of cardiac end points was higher in the trastuzumab group compared with observation (severe congestive heart failure [CHF], 0.60% v 0.00%; symptomatic CHF, 2.15% v 0.12%; confirmed significant LVEF drops, 3.04% v 0.53%). Most patients with cardiac dysfunction recovered in fewer than 6 months. Patients with trastuzumab-associated cardiac dysfunction were treated with higher cumulative doses of doxorubicin (287 mg/m2 v 257 mg/m 2) or epirubicin (480 mg/m2 v 422 mg/m2) and had a lower screening LVEF and a higher body mass index. Conclusion: Given the clear benefit in disease-free survival, the low incidence of cardiac adverse events, and the suggestion that cardiac dysfunction might be reversible, adjuvant trastuzumab should be considered for treatment of breast cancer patients who fulfill the HERA trial eligibility criteria.

Original languageEnglish
Pages (from-to)3859-3865
Number of pages7
JournalJournal of Clinical Oncology
Volume25
Issue number25
DOIs
Publication statusPublished - Sep 1 2007

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial'. Together they form a unique fingerprint.

  • Cite this

    Suter, T. M., Procter, M., Van Veldhuisen, D. J., Muscholl, M., Bergh, J., Carlomagno, C., Perren, T., Passalacqua, R., Bighin, C., Klijn, J. G. M., Ageev, F. T., Hitre, E., Groetz, J., Iwata, H., Knap, M., Gnant, M., Muehlbauer, S., Spence, A., Gelber, R. D., & Piccart-Gebhart, M. J. (2007). Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. Journal of Clinical Oncology, 25(25), 3859-3865. https://doi.org/10.1200/JCO.2006.09.1611